Globe Newswire05.07.19
BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that David Andrew (D.A.) Wallach, a Los Angeles-based investor, recording artist and songwriter, has joined the company's advisory board.
Wallach brings to BioSig extensive experience in advising and investing in early stage technology companies, including SpaceX, Doctor on Demand, Ripple, Glympse, Beam, and Spotify, where he was the official Artist in Residence.
Forbes selected Wallach as one of its 30 Under 30, and Fast Company named him one of the 100 Most Creative People in Business. In 2015, he launched Inevitable Ventures, an investment partnership with multibillionaire Ron Burkle that supports radical entrepreneurs in areas including healthcare, the life sciences, and financial technologies.
“D.A. has impressed us with his outstanding knowledge of bioelectronic medicine and his successful track record of investing in early stage high-potential technology companies. We are convinced that D.A. will become an invaluable addition to our existing Advisory Board due to his innovative thinking and unique business skills,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies, Inc.
The goal of the advisory board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships, and M&A. Current board members include Los Angeles-based political advisor and business leader Sim Farar, San Francisco Bay area-based Kent Bennett Williams, CEO and Principal at Vista Asset Management LLC and Texas-based Dr. Ramachandra Malya, who also is a medical director and consulting nephrologist.
“Having spent some time with the company’s management team, I have been impressed by their dedication to address unmet clinical needs in some of the most challenging areas of medicine. I’m pleased to lend my support to help BioSig grow into a successful commercial company,” commented Wallach.
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and has received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System in August 2018.
Wallach brings to BioSig extensive experience in advising and investing in early stage technology companies, including SpaceX, Doctor on Demand, Ripple, Glympse, Beam, and Spotify, where he was the official Artist in Residence.
Forbes selected Wallach as one of its 30 Under 30, and Fast Company named him one of the 100 Most Creative People in Business. In 2015, he launched Inevitable Ventures, an investment partnership with multibillionaire Ron Burkle that supports radical entrepreneurs in areas including healthcare, the life sciences, and financial technologies.
“D.A. has impressed us with his outstanding knowledge of bioelectronic medicine and his successful track record of investing in early stage high-potential technology companies. We are convinced that D.A. will become an invaluable addition to our existing Advisory Board due to his innovative thinking and unique business skills,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies, Inc.
The goal of the advisory board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships, and M&A. Current board members include Los Angeles-based political advisor and business leader Sim Farar, San Francisco Bay area-based Kent Bennett Williams, CEO and Principal at Vista Asset Management LLC and Texas-based Dr. Ramachandra Malya, who also is a medical director and consulting nephrologist.
“Having spent some time with the company’s management team, I have been impressed by their dedication to address unmet clinical needs in some of the most challenging areas of medicine. I’m pleased to lend my support to help BioSig grow into a successful commercial company,” commented Wallach.
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BioSig has partnered with Minnetronix on technology development and has received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System in August 2018.
